All In Biotech

Drug Trial Radar · NCT03702985

Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer

A Phase II Trial of Capecitabine and Irinotecan With or Without Amifostine in Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Last checked: Nov 19, 2026Latest source record: Jan 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

160

Planned (sponsor's estimate)

Start

May 28, 2018

Primary completion

Nov 1, 2019

Study completion Mar 1, 2020

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study evaluates the addition of Amifostine to capecitabine and irinotecan in neoadjuvant chemoradiation(CRT) in locally advanced rectal cancer. Half of participants will receive capecitabine and along with neoadjuvant radiotherapy, followed by a cycle of XELIRI, while the others will receive capecitabine and irinotecan added by amifostine during CRT, followed by a cycle of XELIRI. All participants will be scheduled to receive surgery 6-8 weeks after the completion of CRT. Then it will depends which regimens the patient would receive according to his or her pathological results.

Conditions

  • Locally Advanced Rectal Cancer

Interventions

  • RadiationRadiation

    Pelvic Radiation: 50Gy/25Fx

  • CapecitabineDrug

    625mg/m2 bid Monday-Friday per week

  • IrinotecanDrug

    80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)

  • AmifostineDrug

    400mg/m2 per week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0Time frame: during neoadjuvant chemoradiation.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.